OXIDIEN PHARMACEUTICALS
Dead / Abandoned — Abandoned — no statement of use filed (as of 31 Mar 2025)
What this means for you
This application is over — abandoned 31 Mar 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98212166
- Mark type
- Stylized text
- Filed
- 06 Oct 2023
- Published for opposition
- 02 Jul 2024
- Abandoned
- 31 Mar 2025
- Attorney of record
- Amber N. Davis
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, substances and products for use in nephrology and urology, namely, for the treatment and prevention of kidney-related disease, namely, kidney stones, hyperoxaluria, hyperoxalemia, and chronic kidney disease
- Class 035 — Advertising and business services: Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval
- Class 042 — Scientific and technological services: Pharmaceutical products development; Development of pharmaceutical preparations and medicines; Pharmaceutical research and development; scientific and technological services, namely, research and development of new products for others, and scientific research in the field of pharmaceutics, and scientific laboratory services; medical and pharmacological research services, namely, scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical preparations, and drugs; natural science services, namely, biological research, and chemical analysis of industrial and clinical fluids; medical and scientific research in the field of pharmaceutical preparations, and drugs; clinical testing, namely, scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical preparations, and drugs; product development of probes, reagents and bioassays for industrial and scientific purposes
Owner
- Oxidien Pharmaceuticals, LLC, Lexington, MA, US
- Oxidien Pharmaceuticals, LLC, Lexington, MA, US
Prosecution history
- 31 Mar 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 31 Mar 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 27 Aug 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Jul 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Jul 2024 — PUBLISHED FOR OPPOSITION
- 12 Jun 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 29 May 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 May 2024 — EXAMINER'S AMENDMENT ENTERED
- 29 May 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 29 May 2024 — EXAMINERS AMENDMENT E-MAILED
- 29 May 2024 — EXAMINERS AMENDMENT -WRITTEN
- 28 May 2024 — ASSIGNED TO EXAMINER
- 10 Jan 2024 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- 14 Oct 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 10 Oct 2023 — NEW APPLICATION ENTERED